drugset / Trial / NCT03402464
Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC
Phase 2
Unknown
30 enrolled
Peking University Cancer Hospital & Institute
Betta Pharmaceuticals Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The study was to evaluate the safety, PFS and ORR of icotinib/dihydroaremisinin (DHA)-based combination therapy in EGFR-mutated, advanced NSCLC patients who have gradually progressed disease after first-line icotinib treatment.
Timeline
- Start
- 2018-01
- Primary completion
- 2019-06-01
- Completion
- 2020-09-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dihydroaremisinin | Unknown | 80 mg | Oral |
| Background | Icotinib | Small molecule | — | — |